Life Science SME

The company is digitising microscopy and laboratory workflows. It has developed unique imaging systems for histopathological microscopy assessment. The solutions for digital imaging and image management are developed and marketed by the company while the downstream procedures for image analysis are provided by third parties software and integrated into an API-portal. The business model is best described as the effort of aggregating the whole diagnostic workflow of a histopathological department in an end-to-end solution with the aim of improving patient care.

The combined hardware/software business generates upfront revenues and cash flows through selling the digital microscope and scanner units with a gross margin of 70% and recurring revenues through SaaS as well as a pay per use model (gross Margin~80-90%) where PreciPoint will be paid according to utilisation on a minimum usage clause.

As of 2020, the market size oft he global digital pathology was valued at $ 553m and is projected to reach $ 1,054m by 2025, growing at a CAGR of 13,8%, with North America taking the biggest share of this market. Key drivers of this growth are the demand to increase lab efficiency, the rising prevalence of cancer, and the growing applications of pathology in the drug development.